Join Today

PMC members shape and advance the future of personalized medicine.
» Sign Up Today

In the Spotlight

Value-Based Healthcare: A Global Assessment

If appropriately designed, value-based health care systems could incentivize the use of personalized medicine technologies that help doctors select the most effective treatment regimen for each patient. In a report titled Value-Based Healthcare: A Global Assessment, The Economist Intelligence Unit examines the extent to which health care systems in countries around the world are aligned with the concepts associated with value-based care. The results of the report will be discussed during a live webinar on November 9, 2016.
» Value-Based Healthcare: A Global Assessment
» Webinar: Building a New Ecosystem of Care: Lessons From Experiments in Value-Based Healthcare

Member News

New Partnership Points to Collaborative Future for Personalized Medicine

A new partnership between Thermo Fisher Scientific and West China Hospital of Sichuan University may point to a future in which pharmaceutical and diagnostic companies regularly work with health care providers on personalized medicine initiatives, says PMC President Edward Abrahams. The institutions will build centers to train pathologists and implement standardized quality control, all with an eye toward a jointly developed, high-impact research platform.
» CenterWatch Weekly

Intermountain, Stanford, Providence to Share Data in Context of 'Moonshot' Task Force
In an unprecedented collaboration, Intermountain Healthcare, the Stanford Cancer Institute and Providence Health & Services have joined forces with Syapse to share genomic and other data. Through the partnership, called the Oncology Precision Network (OPeN), the organizations hope to offer better care to their patients and increase access to clinical trials.
» Syapse press release

Boehringer Ingelheim to Investigate Olmutinib as Option for Patients With Resistance to Other EGFR Inhibitors
Boehringer Ingelheim has announced an effort to study the safety and efficacy of ELUXA (olmutinib), as a treatment option for non-small cell lung cancer (NSCLC) patients. The trials build on earlier data suggesting that ELUXA can improve outcomes for patients who have become resistant to first-line TKI therapies.
» Boehringer Ingelheim press release